In accordance with Disclosure and Transparency Rule 3.1.4R, the Company today announces that it was notified on 28 April 2016 that on 10 March 2016, Hugh Morrison, a PDMR, pledged 2,315 ordinary shares, each having £1.00 nominal value, of the Company (the "Ordinary Shares") as collateral in connection with a margin account, and on 14 April 2016, Mr. Morrison pledged a further 2,000 Ordinary Shares as collateral for the same account (collectively, the "Pledged Shares").
There is no disposal of any of the Pledged Shares. Therefore, Mr. Morrison directly holds 8,815 Ordinary Shares (including the Pledged Shares) and has an entitlement of up to 1,209 Ordinary Shares in connection with his RSUs.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK's Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol "LIVN." For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332